Orexo

Regulatory Filings • Aug 25, 2015

Press release

Orexo's Upcoming Presentations at Events during Second Half 2015

Uppsala, Sweden – August 25, 2015 – Orexo AB (publ) informs today that the company will be presenting at the following events during the fall of 2015.

August 28:	Pareto Securities' 6th Annual Health Care Seminar, Stockholm
September 3:	Redeye Open Investor Forum, Stockholm
October 22:	Release of Orexo Q3 Interim Report followed by audio cast
October 30:	ProHearings Investor Presentation, Stockholm
November 18/19:	Jefferies Autumn 2015 Global Healthcare Conference, London
December 15:	Guggenheim's Boston One-on-One Healthcare Day, Boston

Please visit the pages "Upcoming events" and "Investors" at www.orexo.com for details and further updated information. In case of any additional upcoming events not mentioned above, these will be announced on our corporate web site.

For further information, please contact

Henrik Juuel, EVP and Chief Financial Officer Tel: +46 (0)18-780 88 00, E-mail: ir@orexo.com

About Orexo

Orexo is a specialty pharmaceutical company commercializing its proprietary product Zubsolv® for treatment of opioid dependence in the US. Zubsolv is an advanced formulation of buprenorphine and naloxone using Orexo's unique knowledge and expertise in sublingual drug delivery. R&D is focusing on reformulation of known substances to new improved products that meet great unmet medical needs by using its patented proprietary technologies. Orexo's share is listed on Nasdaq Stockholm Exchange Mid Cap (STO: ORX) and is available as ADRs on OTCQX (ORXOY) in the US. Orexo's global headquarters and R&D are based in Uppsala, Sweden. www.orexo.com.

For information about ZUBSOLV and opioid dependence, please visit www.zubsolv.com and www.outthemonster.com